That would make IMM-124E the only other NASH drug in development alongside Intercept's Ocaliva that has breakthrough therapy status. Going to try to confirm this...
TGN Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27